从伦理到信任:医疗保健领域安全、可靠、有效 AI 的战略护栏
From Ethics to Trust: Strategic Guardrails for Safe, Secure, Effective AI in Healthcare
医疗保健领域在 AI 使用方面仍落后于其他行业,公众信任度也仍然有限,这进一步凸显了战略领导力、明确护栏和负责任实施的必要性。
人们对 AI 的关注更多了,怀疑也更多了,要正确应用 AI 的压力也更大,尤其是考虑到这些应用可能影响患者的生命。随着 AI 更加深入地融入药物研发和临床工作流程,医疗保健和生命科学领域的领导者因此需要展现出合乎伦理的管理能力和技术胜任力,以建立信任并保护患者。
这就是为什么,对于希望借助 AI 实现创新的医疗保健和生命科学组织而言,合乎伦理的 AI 和可信赖的 AI 框架应当成为基本配置。这些彼此不同但相互关联的框架共同构成了一项可辩护的 AI 战略——确保所有与 AI 相关的行动和决策都能够向关键利益相关者作出解释并证明其合理性。二者结合后,团队能够回答两个经过压力测试的关键问题:此 AI 应用存在哪些风险?我们是否有能力降低这些风险?
由以下机构呈现赞助文章医疗保健支付行业面临认知挑战医疗保健支付已不再只是交易。它关乎控制收入周期。而且这种控制越来越不掌握在 ISO 手中。
作者:Lisa Brooks,医疗保健合作副总裁伦理 AI 与可信赖 AI 的区别对于影响 AI 开发和部署方式的制药企业高管、医疗服务提供者和监管机构而言,“伦理 AI”与“可信赖 AI”之间的区别具有重要意义。虽然这些概念可能存在重叠,但在制定战略、护栏和证据要求时,将二者分开考虑是有益的。
伦理 AI 和可信赖 AI 是运营框架,用于塑造组织如何治理、部署 AI 解决方案并赢得对其的信任。二者的相互作用和先后顺序会因具体情境和组织优先事项而异。在实践中,组织可以同时处理伦理 AI 和可信赖 AI,利用可信赖 AI 界定哪些内容能够被工程化和评估,同时由伦理考量指导贯穿整个生命周期的监督。
主要区别在于:伦理 AI 通过价值观、规范和公平性,反映组织的领导立场,审视应该做什么。伦理框架具有专业性,能够平衡政策、技术和业务需求。由于许多伦理考量涉及细微差别和权衡,随着新信息或情境的出现,框架应当能够进行调整。
由以下机构呈现赞助文章自动化医疗实践内部:围绕人而非文书工作重新设计医疗服务通过减少行政负担并围绕人的需求重新设计工作流程,它为最重要的事情创造了空间:临床医生与患者之间的联系。
作者:Michael Blackman,医学博士、工商管理硕士,Greenway Health® 首席医疗官例如,在公共卫生领域使用 AI,利用健康的社会决定因素(SDoH)指导资源分配时,我们依赖的是尊重具体情境的社区层面指标,还是可能让人感到被侵犯或不公平的个人层面信号?在临床试验招募中,如果优化 AI 以预测完成率会降低人群代表性,这是否可以接受?伦理上可辩护的平衡点在哪里?
可信赖 AI 审视的是能够做什么。这些框架关注技术要求(需要构建和工程化什么),并强调可证明的合规性、可靠性、安全性、安保性、透明度和可解释性。可信赖 AI 还会考虑具有约束力的法律以及公认的框架,例如 EU AI Act(法律)和 NIST AI Risk Management Framework(指导文件),这些内容为组织提供负责任 AI 实践方面的建议,并影响可信赖 AI 原则应如何形成证据。
沿用前述示例,如果公共卫生部门确实使用 SDoH(可能是在社区层面),可信赖的实践意味着要围绕患者安全和数据安全进行工程化设计,包括满足 AI 和数据保护法律所需的技术控制措施和访问模式,符合相关标准,并生成关于这些控制措施的可验证证据。对于试验招募,在招募工作中平衡人群多样性与完成试验的可能性,重点将包括对所有亚群体作出准确的完成率预测。招募策略还需要在临床上保持合理,并能够向 FDA 或 EMA 等监管机构进行有理有据的说明。
一体化模型
理解伦理 AI 与可信赖 AI 之间的差异是一回事,将二者付诸实践则是另一回事。问题在于:我们如何同时将这两个框架落地?
伦理 AI 和可信赖 AI 应当在统一的战略监督下相互融合,针对不同用例提供明确的护栏、角色和问责机制。探索使用 AI 检测不良事件的药物研发企业,其风险和工作流程会不同于使用 AI 进行临床文档记录的医院。但二者都需要建立问责结构,以证明 AI 的使用符合伦理、可信赖、负责任且具有可辩护性。
让伦理与信任发挥作用
建立统一的监督和明确的方向需要有意识的协作。各行业和各地区的法规与社会期望都在不断演变。领导者可以通过尽早设定战略护栏、衡量安全和安保结果,并随着标准成熟而更新证据,降低推进工作的风险。
为应对更加严格的审查并展示战略监督、透明度和问责性,组织可以制定自己的框架,在运营效率与患者安全、安保性及伦理护栏之间取得平衡。以下是开始实施时需要考虑的一些事项:
将 AI 确立为战略重点:
从一开始就需要明确意图、影响和技术设计原则,从而将目的、患者安全和安保性内置其中,而不是事后加装。将以伦理为导向的战略立场(为什么)与可信赖的工程标准(是什么)结合起来,可以从第一天起就为团队提供明确的护栏和方向。跨学科领导层(包括临床、产品、AI 科学、安全、隐私和法律领域)共同承担这一立场,并随着证据和法规的成熟不断完善。采用这种方式可以减少后期意外,使试点和开发与医疗保健及生命科学领域的文化和期望保持一致。这有助于减少后期挑战、支持实施并降低运营风险。
正式确定护栏和方向:
战略监督通过明确 AI 如何接受审查和应用来支持创新。在医疗保健和生命科学领域,由高级领导者和技术专家组成的正式伦理与信任监督委员会,可以提供一致的方式来评估相关活动、发现证据缺口并解决问责问题。这一结构有助于团队及早识别高风险或含义不明确的用例,并以患者安全和安保性为首要原则,实施适当程度的审查。当监督与实施工作流并行开展时,组织会在构建过程中处理监管义务、风险和伦理问题,从而让负责任的创新能够更快速、更有信心地推进。
采用分层风险方法:
医疗保健或生命科学组织应在接受高管监督的审查委员会中,由隐私和合规专家提供支持,采用分级风险方法评估 AI 用例——既考虑 AI 的类型,也考虑其在产品生命周期中的位置以及与患者生活的接近程度。这种自适应方法会根据需要对 AI 的风险和可信度进行相应规模的评估(许多应用已经实施了护栏)。例如,文献挖掘和情景建模是在早期研究阶段使用的较低风险 AI 应用,而早期研究也被视为较低风险。相比之下,较高风险的应用(例如用于临床决策支持的大语言模型)由于其复杂性以及与患者护理的接近程度,需要进行更严格的评估。患者安全是必须遵循的原则,也是进行技术和业务权衡时所依据的视角。
构建文化准备度:
这是有效部署 AI 的核心部分,因为团队需要了解这项技术如何融入其工作,以及决策是如何作出的。当领导者解释应用如何支持伦理承诺、患者安全成果、安全标准和业务目标时,AI 项目便能获得推动力。领导者还需要清晰地回答有关工作流程变化、监管要求或人们认为的工作影响等问题。提供结构化的变革管理支持,有助于人们了解 AI 如何为运营目标和患者成果带来积极贡献,从而建立信心,并推动整个组织的采用。
由于 AI 在医疗保健和生命科学领域不可避免地会影响患者及其所接受的护理,因此谨慎实施的需求始终存在。通过战略监督、明确的护栏、患者安全措施和安全工程,组织可以负责任地应用 AI,赢得临床医生、监管机构,尤其是患者的信任。
图片:Pakorn Supajitsoontorn,Getty Images Luk Arbuckle Luk Arbuckle是 IQVIA Applied AI Science 的全球 AI 实践负责人兼首席方法论专家,致力于推动数据和 AI 领域的创新,重点关注伦理、隐私和监管合规。作为公认的思想领袖,Luk 为全球监管机构提供建议,并广泛发表有关 AI 治理和数据保护的文章。
本文通过 MedCity Influencers 项目发布。任何人都可以通过 MedCity Influencers 在 MedCity News 上发表其对医疗保健领域商业和创新的观点。
点击此处了解详情。
Healthcare adoption still trails other industries in AI use, and public trust remains limited, which reinforces the need for strategic leadership, clear guardrails, and responsible implementation.
There’s more attention, more skepticism and more pressure to get AI right, especially knowing these applications can impact patient lives. As AI becomes more integrated into drug development and clinical workflows, leaders across healthcare and life sciences are therefore expected to demonstrate ethical stewardship and technical competence to instill trust and protect patients.
That’s why ethical AI and trustworthy AI frameworks should be table stakes for healthcare and life sciences organizations seeking to innovate with AI. These distinct, but interconnected, frameworks contribute to a defensible AI strategy — one that ensures all AI-related actions and decisions can be explained and justified to key stakeholders. Together, they allow teams to answer two critical, pressure-tested questions: what risks are associated with this AI application, and are we capable of mitigating them?
The differences between ethical AI and trustworthy AI
The distinction between “ethical AI” and “trustworthy AI” is meaningful for pharmaceutical executives, healthcare providers and regulators who influence how AI is developed and deployed. While the concepts can overlap, it’s useful to consider them separately when setting strategy, guardrails and evidence expectations.
Ethical AI and trustworthy AI are operational frameworks that shape how organizations govern, deploy and earn trust for AI solutions. Their interplay and sequence vary depending on context and organizational priorities. In practice, organizations may address ethical and trustworthy AI concurrently, using trustworthy AI to define what can be engineered and evaluated while ethical considerations guide oversight across the lifecycle.
Here’s the main difference: ethical AI examines what should be done by reflecting an organization’s leadership posture, through values, norms and fairness. Ethical frameworks are specialized and balance policy, technology, and business needs. Because many ethical considerations involve nuance and tradeoffs, frameworks should be adaptable as new information or context emerges.
By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®
For example, when using social determinants of health (SDoH) to guide resource allocation using AI for public health, are we relying on community‑level indicators that respect context, or individual‑level signals that could feel intrusive or unfair? In clinical trial recruitment, is it acceptable to optimize AI for predicted completion if that reduces population representativeness, and where is the ethically defensible balance?
Trustworthy AI examines what
can be done. These frameworks focus on technical requirements (what needs to be built and engineered) and emphasize demonstrable compliance, reliability, safety, security, transparency and explainability. Trustworthy AI also accounts for binding legislation and recognized frameworks, such as the EU AI Act (legislation) and the NIST AI Risk Management Framework (guidance), which advise organizations on responsible AI practices shaping how the principles of trustworthy AI are evidenced.
Following the previous examples, if a public health department does use SDoH (perhaps at a community level), trustworthy practice means engineering for patient safety and data security, including technical controls and access patterns needed to satisfy AI and data protection laws, meeting relevant standards, and producing verifiable evidence of those controls. For trial recruitment, balancing population diversity with trial completion likelihood in recruitment efforts, the focus will include accurate completion predictions across all subpopulations. The recruitment strategy also needs to remain clinically sound and defensible to regulators like the FDA or EMA.
A cohesive model
Understanding the differences between ethical and trustworthy AI is one thing. Putting them into practice is another. The question becomes: how do we operationalize both frameworks simultaneously?
Ethical AI and trustworthy AI should weave together under cohesive strategic oversight, providing clear guardrails, roles and accountabilities that adapt by use case. Drug developers exploring AI use for adverse event detection will have different risks and different workflows than a hospital using AI for clinical documentation. But both need accountability structures in place that prove AI use is ethical, trustworthy, responsible and defensible.
Put ethics and trust to work
Building cohesive oversight and clear direction requires deliberate collaboration. Regulations and societal expectations are evolving across industries and regions. Leaders can de-risk progress by setting strategic guardrails early, measuring safety and security outcomes, and updating evidence as standards mature.
To meet heightened scrutiny and demonstrate strategic oversight, transparency and accountability, organizations can develop their own frameworks that balance operational efficiency with patient safety, security, and ethical guardrails. Here are some considerations for getting started:
Establish AI as a strategic priority:
Intent, impact and technical design principles need to be defined at the outset so that purpose, patient safety, and security are built in rather than bolted on. Setting an ethics‑led strategic posture (the why) alongside trustworthy engineering standards (the what) gives teams clear guardrails and direction from day one. Cross‑disciplinary leadership (including clinical, product, AI science, security, privacy, legal) co‑owns this posture and evolves it as evidence and regulations mature. Working this way reduces late‑stage surprises and aligns pilots and development with the culture and expectations of healthcare and life sciences. This helps reduce later‑stage challenges, supports implementation, and lowers operational risk.
Formalize guardrails and direction:
Strategic oversight supports innovation by creating clarity about how AI is reviewed and applied. In healthcare and life sciences, a formal ethics and trust oversight board that brings together senior leaders and technical experts can provide a consistent way to assess activities, surface evidence gaps, and resolve questions about accountability. This structure helps teams identify high‑risk or ambiguous use cases early and apply the right level of scrutiny with patient safety and security as first principles. When oversight runs in parallel with implementation workstreams, organizations address regulatory duties, risk, and ethical questions as part of the build, so responsible innovation moves faster and with confidence.
Leverage a tiered risk approach:
A healthcare or life sciences organization, supported by privacy and compliance experts in a review board with executive oversight, should assess AI use cases through a tiered risk approach — one that considers the type of AI as well as its position in the product lifecycle and proximity to patient lives. This adaptive approach scales the evaluation of AI risk and credibility based on need (where guardrails have already been implemented for many applications). For instance, literature mining and scenario modeling are lower-risk AI applications used in early-stage research, which is also considered lower risk. Whereas higher‑risk applications, such as large language models used in clinical decision support, require more rigorous evaluation because of their complexity and proximity to patient care. Patient safety is the imperative and the lens through which technical and business trade-offs are made.
Build cultural readiness:
This is a core part of deploying AI effectively because teams need to understand how the technology fits into their work and how decisions are being made. AI programs gain traction when leaders explain how applications support ethical commitments, patient-safety outcomes, security standards, and business objectives. Leaders will also need to address questions about workflow changes, regulatory expectations or perceived job impacts with clarity. Providing structured change management support helps people see how AI can contribute positively to operational goals and patient outcomes, which builds confidence and enables adoption across the organization.
The need for careful implementation is constant because AI in healthcare and life sciences inevitably influences patients and their care. With strategic oversight, clear guardrails, patient‑safety measures, and secure engineering, organizations can apply AI responsibly, earning the confidence of clinicians, regulators, and, most importantly, patients.
Photo: Pakorn Supajitsoontorn, Getty Images Luk Arbuckle Luk Arbuckle is Global AI Practice Leader and Chief Methodologist at IQVIA Applied AI Science, driving innovation in data and AI with a focus on ethics, privacy, and regulatory compliance. A recognized thought leader, Luk advises global authorities and publishes widely on AI governance and data protection.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers.
Click here to find out how